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Background. Chronic kidney disease is associated with
higher levels of inflammatory biomarkers. Statins have anti-
inflammatory properties and may attenuate loss of kidney
function. Although inflammation may mediate progressive re-
nal injury, the relation between statin use, markers of inflam-
mation, and the rate of kidney function loss has not been
elucidated. We examined the association between pravastatin
use, levels of C-reactive protein (CRP), soluble tumor necro-
sis factor receptor II (sTNFrii), and the rate of kidney function
loss.
Methods. We performed a post hoc analysis of data from
a randomized placebo controlled trial of pravastatin 40 mg
daily in people with previous myocardial infarction. Glomeru-
lar filtration rate (GFR) was estimated using the Modifica-
tion of Diet in Renal Disease Study (MDRD) GFR equation.
We studied 687 subjects with chronic kidney disease (GFR <
60 mL/min/1.73 m2) who did not experience a cardiovascular
event during follow-up. Multivariate linear regression was used
to study the relation between baseline CRP and sTNFrii and
the rate of kidney function loss in mL/min/1.73 m2/year. Cross-
product interaction terms were used to determine if these rela-
tions varied with pravastatin use.
Results. Median baseline GFR was 54.5 mL/min/1.73 m2 (in-
terquartile range 49.7, 57.8) and median duration of follow-up
was 58 months. Higher baseline CRP level was independently
associated with more rapid kidney function loss (highest tertile
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0.6 mL/min/1.73 m2 per year faster than lowest tertile) (P =
0.001). A similar independent relation was observed between
tertile of sTNFrii and rate of kidney function loss (highest ter-
tile 0.5 mL/min/1.73 m2 per year faster than lowest tertile) (P =
0.006). Subjects with both CRP and sTNFrii in the highest ter-
tile (“inflamed” status) appeared to derive more renal benefit
from pravastatin than those without (P for interaction 0.047). In
these 108 subjects, renal function loss in pravastatin recipients
was 0.8 mL/min/1.73 m2/year slower than placebo (95% CI 0 to
1.5 mL/min/1.73 m2/year slower) (P = 0.039).
Conclusion. Higher CRP and sTNFrii are independently as-
sociated with faster rates of kidney function loss in chronic
kidney disease. Pravastatin appears to prevent loss of kidney
function to a greater extent in individuals with greater evidence
of inflammation, although this was of borderline significance.
These data suggest that inflammation may mediate the loss of
kidney function among subjects with chronic kidney disease and
concomitant coronary disease.
Characteristics predictive of progressive renal function
loss in chronic kidney disease are similar to those asso-
ciated with coronary disease in the general population,
and include male gender, hypertension, diabetes mellitus,
smoking status, dyslipidemia, and proteinuria [1–4]. As
with cardiovascular outcomes, renal outcomes in chronic
kidney disease are improved by blood pressure reduc-
tion [5], tight glycemic control [6], interruption of the
renin-angiotensin system [7, 8], and possibly treatment
of hypercholesterolemia [9, 10].
Evidence of systemic inflammation such as elevated C-
reactive protein (CRP) levels correlates with higher coro-
nary risk in the general population [11], and is associated
with impaired kidney function [12, 13]. Elevated CRP is
associated with endothelial injury and impaired vasodi-
lation, both of which may lead to glomerular damage and
progressive loss of kidney function [14, 15]. Tumor necro-
sis factor-a (TNF-a) is a central proinflammatory agonist
mediator that is generated in a wide variety of innate
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and adaptive immune responses, including some forms
of chronic kidney disease. TNF-a binds to cell surface re-
ceptors on target cells and induces expression of adhesion
molecules, chemokines for leukocytes, and apoptosis in
susceptible cells [16, 17]. Soluble TNF receptors are ele-
vated in the setting of inflammation and chronic kidney
disease [18–20]. Thus, TNF-a also appears to have multi-
ple roles that could mediate progressive renal injury, and
both soluble TNF receptor II (sTNFrii) and CRP may be
used as markers of inflammation.
Given that risk factors for progressive renal disease and
cardiovascular disease are similar, and since chronic kid-
ney disease may constitute a chronic inflammatory state
[12, 21], it is plausible that evidence of systemic inflamma-
tion might predict the rate of renal function loss in chronic
kidney disease. Because elevated serum CRP levels pre-
dict decreased cardiovascular morbidity in response to 3-
hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) re-
ductase inhibitors [22], markers of inflammation might
also identify subjects who are likely to derive renal ben-
efit from statins.
We analyzed data from a previously conducted ran-
domized trial of pravastatin vs. placebo in subjects with
hyperlipidemia and a history of myocardial infarction
[23], considering only participants with chronic kidney
disease [estimated glomerular filtration rate (GFR) <60
mL/min/1.73 m2 body surface area (BSA)] [24]. We tested
the hypotheses that two markers of inflammation (CRP
and sTNFrii) would be associated with more rapid rates
of renal function loss, and that pravastatin would reduce
rates of kidney function loss to a greater extent in subjects
with higher levels of these markers.
METHODS
Study design and patients
The CARE Study was a randomized trial of pravas-
tatin vs. placebo in 4159 individuals with hyperlipidemia
and a history of myocardial infarction [23], and has been
described in detail elsewhere [25]. Briefly, men and post-
menopausal women were eligible if they had had an acute
myocardial infarction between 3 and 20 months before
randomization, were 21 to 75 years of age, and had low-
density lipoprotein (LDL) cholesterol levels of 115 to 174
mg/dL (3.0 to 4.5 mmol/L), fasting glucose levels of no
more than 220 mg/dL (12.2 mmol/L), left ventricular ejec-
tion fractions of no less than 25%, and no symptomatic
congestive heart failure. Patients with serum creatinine
levels >1.5 times the upper limit of normal for the central
study laboratory were excluded from the CARE Study.
After stratification according to clinical center, eligible
participants were assigned by computer-generated ran-
dom order to receive either 40 mg of pravastatin (Prava-
chol) (Bristol-Myers-Squibb, Princeton, NJ, USA) once
daily, or placebo. Treatment allocation was concealed us-
ing a centrally maintained code. Serum creatinine mea-
surements using the alkaline picrate method of Jaffe´ were
made annually at a central study laboratory. Quality as-
surance was maintained through use of standard West-
gard quality control multirules [26], and external pro-
ficiency was provided through the Interlaboratory Sur-
vey Program of the American College of Pathologists
(Northfield, IL, USA). Based on monthly averages of
control materials analyzed several times daily, the per-
cent coefficient of variation for creatinine measurement
ranged from 0.8% at 9.0 mg/dL to 1.8% at 1.4 mg/dL.
Internal and external quality assurance showed the mea-
surement of creatinine to be stable and acceptably cali-
brated throughout the study. Treatment with pravastatin
does not affect serum creatinine measurements [27], and
pravastatin pharmacokinetics are not affected by renal
insufficiency [28].
Definition of kidney disease
The primary index of renal function was estimated
GFR, as calculated by the MDRD equation:
186 × plasma creatinine−1.154 ∗ age in years−0.203
∗ 1.210 (if black) ∗ 0.742 (if female)
where plasma creatinine is in mg/dL. This formula cor-
relates with iothalamate measurements of GFR [24].
Participants with GFR < 60 mL/min/1.73 m2 BSA were
considered to have chronic kidney disease [24] and were
included in this analysis. Proteinuria was defined by trace
or greater urinary protein on baseline dipstick urinalysis.
The primary end point was the rate of change in es-
timated GFR (mL/min/1.73 m2 BSA/year). To minimize
the potential for informative censoring, we included only
those participants from the original CARE Study who did
not experience a cardiovascular outcome during follow-
up. To increase the precision of the estimates of rate
of change in kidney function, we excluded subjects for
whom < three estimates of GFR were available.
Measurement of inflammatory markers
Details of the blood collection and storage procedures
used in the CARE Study have been outlined elsewhere
[25]. Briefly, blood samples were collected in ethylene-
diaminetetraacetic acid (EDTA) at prerandomization
clinic visits (during 1989 to 1991), shipped to a central
collection site on cooled gel packs, and frozen at −80◦C
for future analyses. Stored frozen blood samples from
baseline visits were analyzed specifically to perform the
current analysis in 2004. CRP and sTNFrii assays were
performed simultaneously according to methods de-
scribed by the manufacturers. The concentration of CRP
was determined using an immunoturbidimetric assay
on the Hitachi 917 analyzer (Roche Diagnostics, Indi-
anapolis, IN, USA), using reagents and calibrators from
Denka Seiken (Niigata, Japan). sTNFrii was measured by
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4159 participants in
CARE trial
867 with estimated
GFR <60 mL/min/1.73m2 and blood available
for analysis
126 who experienced cardiovascular events during
follow-up (excluded)
54 with <3 values for estimated GFR or no information
on proteinuria (excluded)
687 included in analysis (moderate
chronic renal insufficiency)
Fig. 1. Flow of participants. GFR is glomeru-
lar filtration rate.
an enzyme-linked immunosorbent assay (ELISA) assay
from R&D Systems (Minneapolis, MN, USA). All assays
were performed without knowledge of treatment assign-
ment.
Statistical analysis
The distribution of CRP values was right-skewed, but
the distribution of sTNFrii was approximately normal. To
facilitate statistical analyses while retaining interpretable
regression coefficients, each of these inflammatory mark-
ers was divided into tertiles. To avoid bias related to
autocorrelation, the annual GFRs were computed and
regressed for each subject onto time, resulting in a sin-
gle measure of the rate of change in kidney function per
subject. These GFR slopes were then used as dependent
variables in univariate and multivariate least squares re-
gression models, which were built using purposeful se-
lection of covariates [29]. Covariates were considered for
inclusion in the multivariable model if they were signif-
icant at the P < 0.25 level in univariate analyses. They
were retained in the multivariable model if they were
significant at the P < 0.1 level, or if they resulted in
an important (>10%) change in the coefficient of inter-
est (usually CRP and/or sTNFrii). Covariates considered
in the multivariate models included age, race, gender,
baseline renal function, systolic blood pressure, baseline
high-density lipoprotein (HDL) cholesterol level, smok-
ing status, diabetic status, use of angiotensin-converting
enzyme (ACE) inhibitors, and baseline proteinuria. For
face validity, baseline proteinuria and systolic blood pres-
sure were retained in all models. After the final model was
built, use of ACE inhibitors, use of pravastatin, smoking
status, and diabetic status were individually forced back
into the model to ensure that these key factors did not
confound the relation of interest. Tests for interaction
were performed using cross-product terms in the regres-
sion models. The regression models were inspected for
outliers and influential observations using leverage vs.
residual2 and residual vs. fitted value plots. Values are
reported as mean ± SD or percentages; 95% CIs are
provided where appropriate. All analyses were intention-
to-treat, and P values are two-sided. Analyses were per-
formed with SAS 8.2 and Stata 8 SE software.
Role of the funding source
The CARE Study and this substudy on kidney dis-
ease were investigator-initiated studies funded by Bristol-
Myers-Squibb. The authors had unlimited access to the
data used in this analysis. The sponsor was entitled to
comment on manuscripts before submission, and the au-
thors could consider these comments, but the rights to
publication reside contractually with the investigators.
The sponsor maintained information on adverse events
and other trial data, as required by federal regulation.
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Table 1. Baseline characteristics of participants with chronic kidney disease, by treatment group
Subjects excluded All subjects included Included placebo Included pravastatin
from analysis in analysis recipients recipients
(N = 180) (N = 687) (N = 344) (N = 343)
Demographic variables
Age years 64.8 ± 6.8 63.5 ± 7.5 63.7 ± 7.4 63.3 ± 7.6
Male (%) 136 (75.6) 523 (76.1) 262 (76.2) 261 (76.1)
Black race (%) 7 (3.9) 10 (1.5) 8 (2.3) 2 (0.6)
Body surface area m2 1.92 ± 0.20 1.91 ± 0.19 1.91 ± 0.19 1.90 ± 0.19
History of hypertension (%) 76 (42.2) 364 (53) 192 (55.8) 172 (50.1)
Current smoker (%) 21 (11.7) 68 (9.9) 32 (9.3) 36 (10.5)
History of diabetes (%) 44 (24.4) 98 (14.3) 55 (16) 43 (12.5)
Medication use
Calcium antagonists (%) 80 (44.4) 292 (42.5) 139 (40.4) 153 (44.6)
ACE inhibitor (%) 49 (27.2) 119 (17.3) 56 (16.3) 63 (18.4)
Aspirin (%) 135 (75) 566 (82.4) 275 (79.9) 291 (84.8)
Beta adrenergic antagonist (%) 67 (37.2) 296 (43.1) 155 (45) 141 (41.1)
Lipid status
Total cholesterol mg/dL 208.1 ± 18.1 209.9 ± 17.1 210.2 ± 16.8 209.7 ± 17.4
LDL cholesterol mg/dL 138.4 ± 14.4 138.5 ± 13.7 138.5 ± 13.7 139.2 ± 14.7
HDL cholesterol mg/dL 40.0 ± 10.8 39.4 ± 9.7 39.8 ± 9.7 39.1 ± 9.6
Triglycerides mg/dL 148.3 ± 52.7 158.4 ± 62.6 159.2 ± 63.2 157.6 ± 62.2
Renal function and blood pressure
Glomerular filtration rate mL/min/1.73 m2a 53.6 (48.6, 57.2) 54.5 (49.7, 57.8) 54.4 (49.5, 57.5) 54.9 (50.0, 57.9)
Serum creatinine mg/dL 1.41 ± 0.24 1.38 ± 0.21 1.39 ± 0.23 1.37 ± 0.20
Proteinuria (dipstick positive) 55 (30.6) 118 (17.2) 59 (17.2) 59 (17.2)
Systolic blood pressure mm Hg 132.7 ± 19.6 132.7 ± 18.9 132.4 ± 19.6 132.5 ± 19.2
Diastolic blood pressure mm Hg 77.6 ± 10.9 78.5 ± 10.5 79.4 ± 10.1 78.9 ± 10.3
Mean arterial pressure mm Hg 96.0 ± 12.5 96.6 ± 11.7 97.0 ± 11.8 96.8 11.7
Inflammatory markers
C-reactive protein mg/La — 2.6 (1.4, 5.3) 2.7 (1.4, 5.4) 2.4 (1.4, 5.1)
Proportion with C-reactive protein in — 229 (33.3) 115 (33.4) 114 (33)
highest tertile (%)
sTNFRii pg/mL — 3719 ± 1143 3711 ± 1208 3715 ± 1176
Proportion with sTNFRii level in — 229 (33.3) 116 (33.7) 113 (33)
highest tertile (%)
Proportion with “inflamed” status (%) — 108 (15.7) 50 (14.5) 58 (16.9)
Abbreviations are: ACE, angiotensin-converting enzyme; LDL, low-density lipoprotein; HDL, high-density lipoprotein; sTNFRii, soluble tumor necrosis factor
receptor II.
Mean ± SD or N (%) except aMedian (25th%, 75th%). Tertiles of C-reactive protein were 0.11 to 1.76, 1.77 to 4.10, and 4.2 to 68.3 mg/L, Tertiles of tumor necrosis
factor receptor II were 16.8 to 3089, 3097 to 3930, and 3931 to 8828 pg/mL. “Inflamed” status was defined by both C-reactive protein and soluble tumor necrosis factor
receptor II in the highest tertile.
RESULTS
Baseline characteristics
Trial flow is shown in Figure 1. There were 687 CARE
participants who were eligible for this analysis and 180
who were excluded (Table 1). Median baseline GFR was
54.5 mL/min/1.73 m2 (interquartile range 49.7, 57.8) and
median duration of follow-up was 58 months in study sub-
jects. The use of ACE inhibitors was similar in pravastatin
and placebo groups at baseline and during follow-up. Bi-
variate analysis showed that baseline GFR was associated
with baseline log CRP and sTNFrii concentrations (both
P < 0.0001), as well as the baseline tertile of CRP and
sTNFrii (both P < 0.0001) (Fig. 2). Results were similar
after multivariate adjustment (all P ≤ 0.0002), indicating
that levels of CRP and sTNFrii in the highest tertile were
both more common at lower levels of kidney function.
The mean GFR of individuals with both CRP and sTN-
Frii in the highest tertile (“inflamed” status) (N = 108)
was 48.5 ± 7.8 mL/min/1.73 m2, significantly lower than
individuals with one or neither of these characteristics
in the highest tertile (53.7 ± 0.22 mL/min/1.73 m2) (P <
0.001).
Kidney function loss in study subjects
Among the 687 subjects, mean rate of decline in esti-
mated GFR was 0.7 ± 1.8 mL/min/1.73 m2/year. Rates of
GFR decline were similar in individuals with proteinuria
at baseline (0.9 ± 2.2 mL/min/1.73 m2/year) compared
to those without (0.6 ± 2. 2 mL/min/1.73 m2/year) (P =
0.13). As previously noted, pravastatin use was not sig-
nificantly associated with kidney function loss when all
subjects with GFR < 60 mL/min/1.73 m2 were consid-
ered (P = 0.53) [9].
Association between inflammatory markers and kidney
function loss
After multivariate adjustment, a significant association
was noted between log-transformed CRP level and the
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Fig. 2. Unadjusted relation between markers of inflammation and
baseline kidney function. The occurrence of C-reactive protein (CRP)
in the highest tertile and the occurrence of tumor necrosis factor re-
ceptor II (TNFrii) in the highest tertile were both more frequent at
lower levels of kidney function. Tertiles of CRP were 0.11-1.76, 1.77-
4.10, and 4.2-68.3 mg/L. Tertiles of TNFrii were 16.8-3089, 3097-3930,
and 3931-8828 pg/mL.
rate of GFR decline (P = 0.002). A similar association
was noted between sTNFrii level and rate of GFR decline
(P = 0.002) (Table 2).
The tertile of CRP level was significantly associated
with the rate of kidney function loss, with higher lev-
els having more rapid loss after adjustment for the ter-
tile of sTNFRii level and other potential confounders
(P = 0.003) (Table 2). A similar relation was observed be-
tween tertile of sTNFrii and the adjusted rate of kidney
function loss (P = 0.008) (Table 2). Subjects with CRP
or sTNFrii in the highest tertile had significantly more
rapid rates of kidney function loss than those in the low-
est tertile [0.6 mL/min/1.73 m2/year faster (P = 0.001) and
0.5 mL/min/1.73 m2/year faster (P = 0.006), respectively]
(Table 2) (Fig. 3). Subjects with both CRP and sTNFrii
in the highest tertile had significantly more rapid rates
of kidney function loss than those with one or neither
characteristic in the highest tertile (0.8 mL mL/min/1.73
m2/year faster) (P < 0.0001).
Interaction between inflammatory markers and effect of
pravastatin on kidney function loss
When CRP and sTNFrii were considered individually,
there was no significant interaction between the highest
tertile of CRP level and the effect of pravastatin on kid-
ney function (P = 0.18), or between the highest tertile of
sTNFrii level and the effect of pravastatin on kidney func-
tion (P = 0.63). However, when both CRP and TNFrii
levels were considered, the 108 subjects with “inflamed”
status appeared to derive more renal benefit from pravas-
tatin than those without (P for interaction 0.047) (Fig. 4).
Specifically, the adjusted rate of kidney function loss in
pravastatin recipients with both CRP and sTNFrii in the
highest tertile was 0.76 mL/min/1.73 m2/year slower than
placebo (95% CI 0.04 to 1.48 mL mL/min/1.73 m2/year
slower) (P = 0.039) (Table 3). In contrast, the rate of kid-
ney function loss in pravastatin recipients without such
evidence of inflammation was no different than placebo
(Table 3).
Because of the previously reported interaction be-
tween proteinuria and renal benefit from pravastatin [9],
we performed an exploratory examination of the effect of
pravastatin on kidney function loss in subjects with both
proteinuria and “inflamed” status (N = 30). We found
that renal benefit appeared particularly favorable in sub-
jects with both characteristics (P for interaction <0.001
compared with subjects who had one or neither charac-
teristic). Renal function loss in pravastatin recipients was
2.25 mL/min/1.73 m2/year slower than placebo in this sub-
group (95% CI 0.86 to 3.63 mL/min/1.73 m2/year slower)
(P = 0.003), compared to no change in the remaining 657
subjects.
DISCUSSION
We found that higher levels of CRP and sTNFrii were
more common at lower levels of kidney function, and
were independently associated with faster rates of kid-
ney function loss. When considered individually, neither
CRP nor sTNFrii level was associated with the magnitude
of renal benefit from pravastatin. However, pravastatin
appeared to reduce rates of kidney function loss predom-
inantly among subjects in whom levels of both markers
were in the highest tertile, especially those who also had
proteinuria. This apparent interaction between inflam-
mation and renal benefit from pravastatin persisted after
controlling for other variables which might affect rates of
renal function loss.
The pathophysiology of some forms of progressive
kidney function loss (such as glomerulosclerosis) and
atherosclerosis is similar. For example, both are accompa-
nied by local upregulation of proinflammatory molecules
[30–32]. Recent work has found that CRP localizes to sites
of vascular injury and potentiates atherosclerotic lesions
in CRP transgenic mice [33, 34]. Inflammatory molecules
may mediate glomerular injury by promoting an influx
of monocytes and macrophages, triggering proliferation
of mesangial cells, and facilitating fibrosis [31, 35–39].
In experimental models, TNF-a causes direct glomerular
injury, and glomerular injury is markedly attenuated in
mice lacking TNF-a [37, 40–42]. In addition, serum TNF-
a levels are associated with the severity of proteinuria in
diabetic nephropathy [43, 44], and reductions in TNF-
a appear to be temporally associated with decreases
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Table 2. Multivariate adjusted association between markers of inflammation and rate of renal function loss (mL/min/1.73 m2/year)
b 95% CI P value
Continuous
Age (per year) −0.045 −0.062, −0.026 <0.0001
Female −0.68 −1.01, −0.36 <0.0001
Systolic blood pressure (10 mm Hg) −0.015 −0.08, 0.05 0.67
Baseline glomerular filtration rate (10 mL/min/1.73 m2) −0.66 −0.90, −0.42 <0.0001
Presence of proteinuria −0.17 −0.52, 0.17 0.33
HDL cholesterol mg/dL 0.018 0.004, 0.033 0.01
Log C-reactive protein [log 9 mg/L)] −0.20 −0.33, −0.072 0.002
Soluble tumor necrosis factor receptor II pg/mL −0.0002 −0.0003, −0.00008 0.002
Tertiles
Age (per year) −0.045 −0.064, −0.027 <0.0001
Female −0.67 −1.00, −0.35 <0.0001
Systolic blood pressure (10 mm Hg) −0.016 −0.09, 0.05 0.65
Baseline glomerular filtration rate (mL/min/1.73 m2) −0.061 −0.085, −0.038 <0.0001
Presence of proteinuria −0.20 −0.55, 0.14 0.25
HDL cholesterol (mg/dL) 0.019 0.004, 0.033 0.01
C-reactive protein tertile 2 (vs. tertile 1)a −0.25 −0.57, 0.071 0.13
C-reactive protein tertile 3 (vs. tertile 1) −0.57 −0.90, −0.24 0.001
Soluble tumor necrosis factor receptor II tertile 2 (vs. tertile 1)b −0.03 −0.35, 0.29 0.85
Soluble tumor necrosis factor receptor II tertile 3 (vs. tertile 1) −0.49 −0.84, −0.14 0.006
Abbreviations are: LDL, low-density lipoprotein; HDL, high-density lipoprotein.
In analysis of continuous, log C-reactive protein and soluble tumor necrosis factor receptor II were entered into the model as continuous variables, and in analysis
of tertiles, the tertile of C-reactive protein and soluble tumor necrosis factor receptor II were entered into the model as categoric variables. Variables considered for
inclusion in the model were age, race, gender, baseline renal function, systolic blood pressure, baseline HDL cholesterol level, smoking status, diabetic status, use of
angiotensin-converting enzyme inhibitors and baseline proteinuria.
CRP sTNFrii Inflamed status
0
-
.
5
-
1
-
1.
5
-
2
0
-
.
5
-
1
-
1.
5
-
2
0
-
.
5
-
1
-
1.
5
-
2C
ha
ng
e 
in
 G
FR
, m
L/
m
in
/1
.7
3m
2 /y
r
Fir
st 
ter
tile
Se
con
d t
ert
ile
Th
ird
 te
rtil
e
Fir
st 
ter
tile
Se
con
d t
ert
ile
Th
ird
 te
rtil
e No Ye
s
Fig. 3. Adjusted relation between markers of inflammation and the rate of kidney function loss. Error bars denote standard error (SE). Inflamed
status was defined by both C-reactive protein (CRP) and soluble tumor necrosis factor receptor II (sTNFrii) levels in the highest tertile. Multivariate
P values for relation with change in kidney function loss: CRP tertile (P = 0.003), sTNFrii tertile (P = 0.008), and inflamed status (P < 0.0001).
Subjects with inflamed status (N = 108)
in urinary protein excretion [43], perhaps due to al-
tered glomerular hemodynamics mediated by reduced
prostaglandin levels [45] or reductions in glomerular per-
meability [46]. Thus, it seems plausible that TNF-a plays
a pathogenic role in progressive nephropathy, especially
when proteinuria is present.
Several small cross-sectional studies demonstrate an
association between impaired kidney function and tu-
mor necrosis factor or its receptors [18, 19, 47, 48]. To
our knowledge, no previous studies examine the relation
between sTNFrii and the rate of kidney function loss in
humans.
Multiple cross-sectional studies document an associa-
tion between CRP and impaired kidney function, includ-
ing data from the third National Health and Nutrition
Examination [18, 19, 49–53]. However, studies examining
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Table 3. Multivariate adjusted effect of pravastatin treatment on adjusted rate of renal function loss (mL/min/1.73 m2/year) in subjects with and
without “inflamed” status
b 95% CI P value
With “inflamed” status (N = 108)
Systolic blood pressure (10 mm Hg) −0.19 −0.36, 0.02 0.03
Baseline glomerular filtration rate (10 mL/min/1.73 m2) −0.57 −1.06, −0.08 0.02
Presence of proteinuria −0.42 −1.25, 0.41 0.32
Pravastatin use 0.76 0.04, 1.48 0.039
Without “inflamed” status (N = 579)
Age (per year) −0.056 −0.07, −0.04 <0.0001
Systolic blood pressure (10 mm Hg) 0.01 −0.07, 0.09 0.82
Baseline glomerular filtration rate (10 mL/min/1.73 m2) −0.055 −0.082, −0.028 <0.0001
Presence of proteinuria −0.18 −0.57, 0.21 0.36
High-density lipoprotein cholesterol mg/dL 0.017 0.003, 0.031 0.02
Pravastatin use 0.02 −0.26, 0.30 0.89
Subjects with both C-reactive protein and tumor necrosis factor receptor II in the highest tertile were considered to have “inflamed” status. The coefficient for
pravastatin use represents the benefit of pravastatin treatment on the rate of kidney function loss in mL/min/1.73 m2 per year (positive values represent rate of
loss which is slower than placebo). Variables considered for inclusion in the model were age, race, gender, baseline renal function, systolic blood pressure, baseline
high-density lipoprotein cholesterol level, smoking status, diabetic status, use of angiotensin-converting enzyme inhibitors, and baseline proteinuria.
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Fig. 4. Adjusted effect of treatment on the rate of kidney function loss. Error bars denote standard error (SE). Inflamed status was defined by both
C-reactive protein (CRP) and soluble tumor necrosis factor receptor II (sTNFrii) levels in the highest tertile. Tests for interaction with pravastatin
use: CRP (P = 0.18), sTNFrii (P = 0.63),and inflamed status (P = 0.047). Subjects in highest tertile of CRP (N = 229), subjects in highest tertile of
sTNFrii (N = 229), and subjects with inflamed status (N = 108).
the relation between CRP and the rate of kidney func-
tion loss have reached conflicting results. A small study
in humans with IgA nephropathy found that CRP levels
predicted more rapid loss of kidney function, but these
authors did not control for other potential mediators of
renal loss such as proteinuria and hypertension [54]. On
the other hand, a larger study of 804 humans with mod-
erate to severe chronic kidney disease found no associa-
tion between CRP and renal function loss [55]. The latter
study had several important strengths, including a range
of different underlying renal diseases, direct measure-
ment of GFR (rather than estimation as in the current
study), and rigorous methodology. However, follow-up
was short (mean 2.2 years), there was limited variability
in observed CRP values, and coronary disease was infre-
quent among participants in that study (<10%). These
differences in study design and population may explain
the discrepant findings compared with the current study.
Since statins reduce CRP and interfere with multi-
ple other inflammatory pathways [19–25], the interac-
tion between “inflamed” status and the renal benefit of
pravastatin would support a pathophysiologic role for in-
flammation in at least some subjects with chronic kidney
disease, and suggest that other therapies which reduce or
prevent inflammation might be of benefit. This hypothe-
sis is supported by recent data which suggest that pravas-
tatin reduces TNF-a and sTNFrii [56, 57]. An alternative
possibility is that oxidative stress may have been partially
responsible for the apparent interaction between inflam-
mation, pravastatin use, and kidney function loss. This
hypothesis is supported by observations that markers of
oxidative stress are correlated with markers of inflam-
mation in chronic kidney disease [58], and that statins
reduce markers of oxidative stress. However, the role of
oxidative stress in progressive chronic kidney disease is
yet to be conclusively determined, and unfortunately, we
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did not have access to markers of oxidative stress in the
current analysis.
Our study has limitations that should be considered.
First, renal function in the current analysis was esti-
mated using the MDRD GFR formula (a recommended
means of estimating kidney function) rather than mea-
sured directly. Although iothalamate measurement of
GFR would have been preferable, the error associated
with use of the MDRD equation was probably reduced
because of the central study laboratory. Second, although
the serum creatinine assay used in the current study was
not calibrated against a reference laboratory, lack of cal-
ibration would presumably affect all serum creatinine
measurements equally, and would thus not affect the es-
timation of rates of change in kidney function. Third,
since the cause of renal disease in study subjects is un-
known, and since all had coronary disease at baseline
without recurrent events during follow-up, the generaliz-
ability of these findings is uncertain. However, given the
frequent coexistence of renal and cardiovascular disease,
such individuals are common in the general population
[59]. Fourth, the number of subjects in some subgroups
was small, and thus these findings must be viewed as
hypothesis-generating, especially since P values for some
analyses were of marginal significance. Fifth, we used an
arbitrary definition of inflammation that was based on
the distribution of values observed in our population (ter-
tiles) rather than an objective definition. Sixth, although
we attempted to reduce bias due to informative censoring
by excluding subjects who experienced a cardiovascular
event during follow-up, it may have been preferable to in-
clude all participants in this analysis. Although we cannot
rule out the possibility that this exclusion resulted in bias,
we believe that it is more likely to have reduced gener-
alizability instead (i.e., applicability to participants who
experienced recurrent cardiovascular events). Seventh,
the blood specimens we used to measure the markers of
inflammation were collected as long as 15 years before the
assays were performed. Previous work found that levels
of CRP and sTNFrii appeared to remain stable in frozen
specimens over an interval of 4 years [60]. While we can-
not exclude the possibility that the longer-term storage
of specimens in the current analysis influenced our re-
sults, this would be expected to introduce random error,
suggesting that performing the assays immediately after
blood collection may have strengthened our results. Fi-
nally, there was no significant interaction between the ef-
fect of pravastatin and inflammation as defined in terms
of either CRP alone or sTNFrii alone, in contrast with
the findings when inflammation was defined in terms of
both biomarkers (both CRP and sTNFrii in the highest
tertiles). It is possible that the latter definition was more
specific for clinically relevant inflammation (thus increas-
ing statistical power to demonstrate the interaction), or
that the interaction depends on inflammatory pathways
which involve simultaneous elevation of CRP and sTN-
Frii. Since this was a post hoc analysis, our findings require
confirmation by additional studies.
CONCLUSION
Levels of CRP and sTNFrii were independently asso-
ciated with the severity of renal insufficiency in people
with coronary disease, and elevated levels of both mark-
ers appeared to be associated with increased renal benefit
from pravastatin. These findings support the hypotheses
that inflammation may mediate some types of progressive
renal disease, and that statins and possibly other anti-
inflammatory therapies may be of clinical benefit.
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